{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.6","upperLimit":"48.7","value":"30.3"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.0","upperLimit":"51.8","value":"33.3"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.6","upperLimit":"48.7","value":"30.3"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.4","upperLimit":"54.9","value":"36.4"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"This refers to the percentage of participants with a reduction of growth hormone (GH) response rates to \\<2.5 ug/L over time.","dispersionType":"95% Confidence Interval","groups":[{"description":"All patients randomized regardless of pasireotide LAR dose.","id":"OG000","title":"Pasireotide LAR - All Participants"}],"paramType":"NUMBER","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the study treatment they have been assigned to during the randomization procedure.","reportingStatus":"POSTED","timeFrame":"Months 3, 6, 9, 12","title":"Percentage of Overall Participants With the Reduction of GH Levels to <2.5 ug/L by Visit (Core Phase)","type":"SECONDARY","unitOfMeasure":"Percenage of participants"}